EUVIMEDEUVIMED entdecken
Crossref

A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis

Sean A Freeman, Roland S Liblau iD

Brain · 17.10.2026

DOI: 10.1093/brain/awag360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 17.10.2026. Verfasst von Sean A Freeman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Toulouse University Hospitals, Toulouse, France. Die Arbeit nennt 9 Literaturangaben. Gefördert von: France-SEP, French MS society, Sobek Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Neurology, Toulouse University Hospitals, Toulouse, France.
  • University of Toulouse, INSERM, CNRS, Infinity - Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
  • Department of Immunology, Toulouse University Hospitals, Toulouse, France.

ORCID-Profile: Roland S Liblau

Förderung

  • France-SEP
  • French MS society
  • Sobek Foundation

Zitieren

APA

Freeman, S. A., & Liblau, R. S. (2026). A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis. Brain. https://doi.org/10.1093/brain/awag360

Vancouver

Freeman SA, Liblau RS. A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis. Brain. 2026. doi:10.1093/brain/awag360

BibTeX
@article{Freeman2026,
  author = {Freeman, Sean A and Liblau, Roland S},
  title = {A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag360}
}
Kostenlos starten →